Clinical Trial

A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity. Participants will receive either cagrilintide or placebo, and which treatment participants get is decided by chance. Cagrilintide is the treatment being tested, while placebo looks like the study medicine but does not contain any active medicine. The study will last for about 30 weeks.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-16
Trial Details
NCT Number NCT07557953
Lead Sponsor Novo Nordisk A/S
Conditions Overweight, Obesity
Enrollment 120 participants
Start Date 2026-04-30
Primary Completion 2027-04-13 (estimated)
Study Completion 2027-04-13 (estimated)
Updated on ClinicalTrials.gov 2026-05-15